Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790010 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
A Phase 1 study of Melanoma, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 3
- Study locations
NCT00790010: Completed Phase 1 study of Melanoma, sponsored by Dana-Farber Cancer Institute.
NCT00790010 is a Phase 1 study of Melanoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 46 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00790010, a Phase 1 study of Melanoma, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the participants melanoma worsens.
Conditions Studied
Interventions
- DRUG Bevacizumab Plus Ipilimumab Cohort 1
- DRUG Bevacizumab Plus Ipilimumab Cohort 2
- DRUG Bevacizumab Plus Ipilimumab Cohort 3
- DRUG Bevacizumab Plus Ipilimumab Cohort 4
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2009-02-26 |
| Est. Completion | 2018-06-22 |
| Phase | Phase 1 |
What the finished NCT00790010 record still lists
NCT00790010 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab Plus Ipilimumab Cohort 1 is the first listed.
NCT00790010 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00790010 about?
NCT00790010 is a clinical study titled "Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma". The purpose of this research study is to determine the safety of using the study drugs bevacizumab and ipilimumab together, and the doses in combination which can be given to people safely. This study also seeks to investigate whether using both study drugs lengthens the amount of time before the pa...
What is the current status of trial NCT00790010?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2009-02-26. Estimated completion is 2018-06-22.
What conditions does trial NCT00790010 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00790010?
The interventions under investigation include: Bevacizumab Plus Ipilimumab Cohort 1 (DRUG), Bevacizumab Plus Ipilimumab Cohort 2 (DRUG), Bevacizumab Plus Ipilimumab Cohort 3 (DRUG), Bevacizumab Plus Ipilimumab Cohort 4 (DRUG).
Who is sponsoring clinical trial NCT00790010?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00790010 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00790010's enrollment target sits among peer trials
46 171st of 266 higher than 95 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI